Shunrong Li
Overview
Explore the profile of Shunrong Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
514
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin Q, Li S, Shang T, Gui X, Zhu L, Yang Y, et al.
BMJ Open
. 2025 Feb;
15(1):e089188.
PMID: 39894515
Objective: Our study aims to evaluate the spatial and temporal changes of breast-conserving surgery (BCS) rates and influential factors of BCS in Guangdong Province, China. Design, Setting And Participants: This...
2.
Liang Z, Li S, Pan Z, Duan Y, Ouyang Q, Zhu L, et al.
Cancer Immunol Res
. 2024 Dec;
13(3):337-352.
PMID: 39715293
CD8+ T-cell abundance is insufficient to assess antitumor immunity and shows poor performance in predicting breast cancer prognosis and immunotherapy response, presumably owing to the complexity of CD8+ T-cell functionalities....
3.
Chen X, Huang H, Huang H, Yong J, Zhu L, Chen Q, et al.
Nat Commun
. 2024 Oct;
15(1):9144.
PMID: 39443446
Oral corticosteroids represents the most prevalent treatment for idiopathic granulomatous mastitis. Ductal lavage with triamcinolone acetonide and antibiotics followed by observation (DL-OBS) has emerged as a novel strategy, but a...
4.
Chen H, Gui X, Zhou Z, Su F, Gong C, Li S, et al.
Breast
. 2024 Apr;
75:103733.
PMID: 38615482
Introduction: The impact of distinct estrogen receptor (ER) and progesterone receptor (PR) expression patterns on tumor behavior and treatment outcomes within HER2-positive breast cancer is not fully explored. This study...
5.
Yang Y, Jin L, Li Y, Rao N, Gong C, Li S, et al.
Chin J Cancer Res
. 2024 Mar;
36(1):55-65.
PMID: 38455369
Objective: Despite cardiotoxicity overlap, the trastuzumab/pertuzumab and anthracycline combination remains crucial due to significant benefits. Pegylated liposomal doxorubicin (PLD), a less cardiotoxic anthracycline, was evaluated for efficacy and cardiac safety...
6.
Li S, Zhang S, Zhang X, Yan J, Wang S, Tan L, et al.
BMC Surg
. 2024 Feb;
24(1):53.
PMID: 38355459
Background: Breast cancer surgeries involving MS-TRAM/DIEP breast reconstruction has traditionally been collaborative efforts between breast surgeons and plastic surgeons. However, in our institution, this procedure is performed by dual-trained breast...
7.
Ma J, Chen K, Li S, Zhu L, Yu Y, Li J, et al.
Eur Radiol
. 2023 Sep;
34(3):1774-1789.
PMID: 37658888
Objectives: Accurate preoperative estimation of the risk of breast-conserving surgery (BCS) resection margin positivity would be beneficial to surgical planning. In this multicenter validation study, we developed an MRI-based radiomic...
8.
Zeng W, Xiong L, Wu W, Li S, Liu J, Yang L, et al.
Oncogene
. 2022 Nov;
42(3):224-237.
PMID: 36418470
The heterogeneity of cancer-associated fibroblasts (CAFs) might be ascribed to differences in origin. CD10 and GPR77 have been reported to identify a chemoresistance-inducing CAF subset in breast cancer. However, the...
9.
Liu X, Lu Y, Huang J, Xing Y, Dai H, Zhu L, et al.
Cancer Cell
. 2022 Nov;
40(11):1341-1357.e13.
PMID: 36379207
The leukocyte Fcγ receptor (FcγR)-mediated response is important for the efficacy of therapeutic antibodies; however, little is known about the role of FcγRs in other cell types. Here we identify...
10.
Ouyang Q, Li S, Gao M, Zhu L, Xu S, Meng S, et al.
Breast
. 2021 Mar;
57:36-42.
PMID: 33711698
Background: Loss to follow-up (LTFU) during post-operative surveillance of breast cancer patients is detrimental. The pattern of LTFU and its risk factors in Chinese breast cancer patients remains unknown. Method:...